CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies

CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies

Abstract Treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) requires new therapy options, especially for patients uneligible for intense chemotherapy or with relapsed or refractory disease. CLEVER-1 is a myeloid checkpoint protein, which can be targeted with a therapeutic f...

Full description

Saved in:
Bibliographic Details
Main Authors: Sofia Aakko, Arno Ylitalo, Heikki Kuusanmäki, Jenna H. Rannikko, Mari Björkman, Jami Mandelin, Caroline A. Heckman, Mika Kontro, Maija Hollmén
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Acute myeloid leukemia
Myelodysplastic syndrome
Bexmarilimab
CLEVER-1
Stabilin-1
Immunotherapy
Online Access:https://doi.org/10.1038/s41598-025-01675-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-01675-y

Similar Items